Topical Alprostadil for Female Sexual Arousal Disorder
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Approximately 300 patients with female sexual arousal disorder who meet eligibility criteria
will be enrolled and randomized to receive either active drug or matching placebo. After a
two-month, non-treatment period, patients will receive study drug for 6 months and will
record information about sexual encounters in a daily diary. Study drug will be applied
directly to the genital area 30-60 minutes before initiation of sexual activity. The endpoint
of the study is based on the use of a standard measure of sexual function (FSEP).